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Abstract
CYP2D6 belongs to the cytochrome P450 superfamily of enzymes and plays an important role in the metabolism of 20–
25% of clinically used drugs including antidepressants. It displays inter-individual and inter-ethnic variability in activity
ranging from complete absence to excessive activity which causes adverse drug reactions and toxicity or therapy failure
even at normal drug doses. This variability is due to genetic polymorphisms which form poor, intermediate, extensive or
ultrarapid metaboliser phenotypes. This study aimed to determine CYP2D6 alleles and their frequencies in the United
Arab Emirates (UAE) local population. CYP2D6 alleles and genotypes were determined by direct DNA sequencing in 151
Emiratis with the majority being psychiatric patients on antidepressants. Several new alleles have been identified and in
total we identified seventeen alleles and 49 genotypes. CYP2D6*1 (wild type) and CYP2D6*2 alleles (extensive
metaboliser phenotype) were found with frequencies of 39.1% and 12.2%, respectively. CYP2D6*41 (intermediate
metaboliser) occurred in 15.2%. Homozygous CYP2D6*4 allele (poor metaboliser) was found with a frequency of 2%
while homozygous and heterozygous CYP2D6*4 occurred with a frequency of 9%. CYP2D6*2xn,c a u s e db yg e n e
duplication (ultrarapid metaboliser) had a frequency of 4.3%. CYP2D6 gene duplication/multiduplication occurred in
16% but only 11.2% who carried more than 2 active functional alleles were considered ultrarapid metabolisers. CYP2D6
gene deletion in one copy occurred in 7.5% of the study group. In conclusion, CYP2D6 gene locus is heterogeneous in
the UAE national population and no significant differences have been identified between the psychiatric patients and
controls.
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Introduction
Interethnic variation in the capacity to metabolize drugs is
mainly due to genetic constitution [1]. Recent advances in
pharmacogenomics elucidated that some variations in DNA
sequences recognized as single nucleotide polymorphisms (SNPs)
may explain some of the variability in drug metabolizing enzyme
activities. These contribute to drug-induced adverse reactions,
toxicity, and therapeutic responses in different ethnic groups [2].
The best characterized genetically determined variations in
antidepressant drug metabolism are those associated with the
polymorphic N-acetyltransferase, NAT2, and two polymorphic
cytochrome P450s involved with oxidation reactions, CYP2D6
and CYP2C19, all of which show marked interethnic differences
in catalytic activity and allele distribution [3]. Whereas the clinical
significance of the CYP2C19 polymorphism is uncertain, the
clinical consequences of the CYP2D6 polymorphism are well
established [4,5].
The potential importance of interethnic differences in CYP2D6
gene structure and expression lies in the large number of drugs
whose elimination is catalysed by CYP2D6. These include tricyclic
antidepressants and antipsychotics [6]. The CYP2D6 locus is
highly polymorphic and currently more than 120 variant CYP2D6
alleles have been described (www.cypalleles.ki.se/cyp2d6.htm).
These alleles can be divided into; 1) alleles resulting in no
functional product (poor metabolizers, PMs); 2) alleles causing a
reduced rate of metabolism (intermediate metabolizers, IMs); 3)
alleles causing ultrarapid metabolism (ultra-rapid metabolizers,
UMs); and 4) alleles with no important functional consequences
(extensive metabolizers, EMs) [7] Given the relatively wide spread
use of CYP2D6-metabolised medications, including antidepres-
sants, and limited availability of data regarding the alleles and
genotypes in Emiratis, this study was undertaken to determine
CYP2D6 alleles and their frequencies, using direct DNA
sequencing of the full coding regions and large parts of the
intronic sequences, in this population.
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Identification of new CYP2D6 alleles
The DNA sequence analysis of all the coding regions, the splice
sites and large parts of the intronic regions was carried out for 151
subjects from the UAE local population. This included 50 healthy
controls and 101 subjects on antidepressants. Eight out of 151
subjects had new alleles and new genotypes (Table 1 and 2).
CYP2D6*105 was the only new homozygous genotype where we
found a novel mutation c.1097T.C (g.3268T.C) which causes
p.F366S change in the corresponding protein. This mutation is
accompanied by the two common SNPs, namely p.R296C and
p.S486T (http://www.cypalleles.ki.se/cyp2d6.htm) in a homozy-
gous state. The other new alleles were unique in their
combinations. Five patients were carrying unreported combina-
tions of known SNPs with some unknowns (Table 2). Both new
SNPs g.1783 A.C and g.4028C.A were intronic thus their effect
on the enzyme function is not clear. The ascertained haplotypes in
these subjects were undetermined due to the heterozygosity of
some of their SNPs. Parents were not included in this study and
therefore it was not possible to assign the alleles.
CYP2D6 allele frequencies among 151 Emiratis
Within our sequenced study group (n=151, 302 alleles) 17
different alleles were identified in which CYP2D6*1 occurred in the
highestfrequency of39.1%(n=118) (Table3).Thiswasfollowed by
CYP2D6*41 with a frequency of 15.2% (n=46), while CYP2D6*2,
CYP2D6*4, CYP2D6*2xn, CYP2D6*39 and CYP2D6*10 had
frequencies of 12.2%, 9%, 4.3%, 4% and 3.3%, respectively.
Frequencies of CYP2D6 functional alleles among 151 UAE
individuals
As shown in table 4 there were only 3 (2%) individuals out of
151 who carried no functional alleles at all. Of the 151 subjects, 27
(17.9%) had only one active allele. The majority carried two active
alleles with a frequency of 68.9%, whereas 17 (11.3%) individuals
were carrying more than two active alleles.
Frequency of CYP2D6 Genotypes and their predicted
phenotypes
CYP2D6*1, CYP2D6*2 and CYP2D6*39 encode for EMs
phenotype in both homozygous and heterozygous forms.
CYP2D6*10 and CYP2D6*41 encode for IMs phenotype but only
in the homozygous form or when it is combined with one of the
poor metaboliser alleles such as CYP2D6*4 which only encode for
a PM phenotype in the homozygous form [8–10]. CYP2D6*2xn
which indicates the presence of gene duplication encode for a UMs
phenotype [11].
In addition to the new genotypes described in table 2, we found
44 different already known genotypes among our study group
(Table 5). Twenty three out of the 44 genotypes were assigned
under EMs phenotype (homozygous or heterozygous). Twelve out
of the 44 were genotypes associated with duplication or multi-
duplication in one of their alleles and they were assigned under
UMs phenotype. Eight out of 44 genotypes were assigned as IMs
phenotype. One genotype was predicted to have PM phenotype.
In the subjects studied (n=151) the following CYP2D6 genotypes
were identified with the highest occurrence:*1/*1(n=31),*1/*2
(n=17),*1/*41(n=14),*1/*4(n=8), *41/*41(n=8), *4/*41 (n=6),
*2/*39 (n=4)and*1/*2xn (n=5) (Table 5). Out of the 151 study
group 2% (n=3) were poor metabolizers carrying the *4/*4
genotype.
Discussion
The impact of CYP2D6 polymorphisms on the clinical outcome
of psychoactive drugs has been extensively described in the
literature [12]. CYP2D6 has more than 120 allelic variants
resulting from point mutations, rearrangements, additions,
deletions and duplications. Several studies have shown that the
frequencies of the alternative CYP2D6 phenotypes vary signifi-
cantly among different ethnic groups [2,13,14]. Examples of these
ethnically specific markers are CYP2D6*17, found in Africans, and
CYP2D6*10, found in Asians. Both result in slower metabolism of
CYP2D6 substrates (such as risperidone and paroxetine), which
result in higher plasma concentrations thereby needing lower
doses for therapeutic effect [8,12,15,16].
Duplications or multiplications of the CYP2D6 gene occurs in
1% of Swedes, 5% of Spanish, 29% of Ethiopians and 19% of
Arabs results in an increased number of enzymes available for
metabolic processes [3,7,17]. This is called ultrarapid metaboliza-
tion. Patients with these mutations will require higher doses of
medications to achieve the therapeutic response. UMs were
previously regarded as ‘‘noncompliant’’ because they did not
respond to the standard medication doses administered [18].
CYP2D6 genotypic frequency information had been determined
for most populations around the world [12]. They displayed
significant interethnic differences in CYP2D6 allele frequencies [1]
resulting in variable percentages of PMs, IMs, EMs and UMs in a
given population. This is the first study to genotype CYP2D6 gene
in UAE local population. However, the incidence of different
Table 1. New alleles found in CYP2D6 among our UAE study group.
New Alleles DNA change
¥ Protein
CYP2D6*102 Intron 1 conversion with CYP2D7 (214–245); 310G.T; 972C.T;
1661G.C; 2850C.T; 3384A.C; 3790C.T; 4180G.C; 4481G.A
A90V; R296C; S486T
CYO2D6*103 Intron 1 conversion with CYP2D7 (214–245); 310G.T;972C.T;1661G.C;
1749A.G;2850C.T; 3384A.C; 3790C.T; 4180G.C; 4481G.A
A90V; N166D; R296C;
S486T
CYP2D6*104 Intron 1 conversion with CYP2D7 (214–245); 310G.T; 843T.G; 1661G.C;
1720A.T; 2850C.T; 3384A.C; 3790C.T; 4180G.C; 4481G.A
E156A; R296C; S486T
CYP2D6*105 Intron 1 conversion with CYP2D7 (214–245); 310G.T; 746C.G; 843T.G;
1661G.C; 2850C.T; 3268T.C; 3384A.C; 3790C.T; 4180G.C; 4481G.A
R296C; F366S; S486T
Nucleotide variations in bold are the major SNPs/alterations responsible for the phenotype of the corresponding allele.
Nucleotide and amino acid variations underlined are novel and have not been reported previously in the CYP2D6 allele nomenclature database.
¥All nucleotide changes are based on Genbank accession number M33388* following the instructions in database http://www.cypalleles.ki.se/cyp2d6.htm.
doi:10.1371/journal.pone.0028943.t001
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challenge to be characterized because of the huge ethnic diversity
that exists in the country.
The novel variant p.F366S found in this population has not
been reported elsewhere and its clinical impact is unknown, but
theoretically and based on bioinformatics tools it could be
clinically significant. It changed phenylalanine which is a
hydrophobic large amino acid into serine which is a polar
uncharged small amino acid. The phenyl ring on the phenylal-
anine probably interacts with the beta sheet and changes it into
small hydrophilic molecule thus disrupting the reaction and the
structure (Figure 1). Moreover, this amino acid substitution is
predicted to probably be protein damaging based on analysis using
PolyPhen program for prediction of functional effect of human
SNPs (http://genetics.bwh.harvard.edu/pph/). Unfortunately, no
plasma was available for the homozygous subject, thus we were
unable to determine his metabolic ratio (MR).
CYP2D6 allele frequencies in our UAE study group were
compared with frequencies seen in other ethnic populations.
According to Toscano et al. [19] 1,*2 and*41 are the three most
frequent CYP2D6 functional alleles. This is similar to our findings
as the said alleles occurred in the highest frequencies namely: *1
(39.1%), *41 (15.2%) and *2 (12.2%). Unlike other populations
[19], CYP2D6*41 occurred more frequently than CYP2D6*2 in
UAE. In the Croatian population the frequencies of polymorphic
CYP2D6*2,*3, *4,* 5, and * 6 alleles were 4%, 2.8%, 14%, 1%,
and 1.5%, respectively. The most frequently observed null allele
was CYP2D6*4, which accounted for 72% of all null alleles.
Among the Croatian population studied, 60% of the subjects had
EM genotype, 33% were IMs, and 3% exhibited the PM
genotype. Four percent exhibited the UM genotype due to
amplified CYP2D6 gene (CYP2D6*2 allele) [20]. The allele
frequency of CYP2D6*4; the most common defective allele among
Caucasians (25%); was 14% in Croatians [20] and only 3.5% in
the Saudi population [21] and 2% in the UAE population. Two
other alleles, CYP2D6*10 (47–70% in Asians) and CYP2D6*17
(25–40% in blacks), are common in certain populations resulting
in diminished enzyme activity. Both were found only at low
frequencies of 3.0% each in the Saudi Arabian population [21]
and 3.3% and 2.5% respectively, in the UAE population.
PMs alleles (e.g.*3,*4,*4xn,*5,*6,*7,*8,*11 or *45) cause absent
enzymatic activity and, possibly, an increased risk of adverse drug
reactions even with routine therapy with CYP2D6 substrates.
CYP2D6*3,*4,*5,*6 form 93–97% of the PM phenotypes in
Caucasians while other inactivating alleles form less than 1%
[22,23]. CYP2D6*4 is the most common defective allele in
Caucasians with a frequency of 20–25% in both heterozygous
and homozygous forms but only homozygous CYP2D6*4 is
associated with the PM phenotype [24]. Heterozygous and
homozygous CYP2D6*4 were found with a frequency of 9% in
Table 2. New genotypes found in CYP2D6 among our UAE study group.
New Genotypes DNA change
¥ Protein change
Genotype 1 Homozygous SNPs: Intron 1 conversion with CYP2D7 (214–245);
310G.T; 843T.G; 1661G.C; 2850C.T; 3384A.C; 3790C.T;
4180G.C. Heterozygous SNPs: 984A.G/A; 2661G.A/G; 4028C.A/C
H94R; R296C; S486T
Genotype 2 Homozygous SNPs:310G.T. Heterozygous SNPs 2606G.A/G; 2610T.A/T E278K; M279K
Genotype 3 Homozygous SNPs: 310G.T; 1661G.C; 3183G.A; 3384A.C; 4180G.C.
Heterozygous SNPs: 100C.T/C; 1039C.T/C; 2850C.T/C; 4401C.T/C
P34S; R296C; V338M; S486T
Genotype 4 Homozygous SNPs: 310G.T; 1661G.C; 2850C.T; 3384A.C; 3790C.T;
4180G.C; 4481G.A. Heterozygous SNPs: Intron 1 conversion
with CYP2D7(214–245);1749A.G/A; 1783A.C/A; 2988G.A/G
N166D; R296C; Splicing defect; S486T
Genotype 5 Homozygous SNPs: 4481G.A
Heterozygous SNPs: Intron 1 conversion with CYP2D7 (214–245); 310G.T/G;
843T.G/T; 1661G.C/G; 1749 A.C/A; 1783 A.C/A; 2850C.T/C;
3384A.C/A; 3790C.T/C; 4180G.C/G
N166D; R296C; S486T
Nucleotide variations in bold are the major SNPs/alterations responsible for the phenotype of the corresponding allele.
Nucleotide and amino acid variations underlined are not reported in CYP2D6 allele nomenclature database.
¥All nucleotide change is based on Gene M33388* following the databasehttp://www.cypalleles.ki.se/cyp2d6.htm.
doi:10.1371/journal.pone.0028943.t002
Table 3. CYP2D6 allele frequencies among 151 (302 alleles)
UAE nationals.
Alleles presence as
homozygous or heterozygous
Allele frequency %.
N=151. 302 alleles total
CYP2D6*1 39.1
CYP2D6*41 15.2
CYP2D6*2 12.2
CYP2D6*4 9
CYP2D6*2xn 4.3
CYP2D6*39 4
CYP2D6*10 3.3
CYP2D6*New 2.6
CYP2D6*35 2
CYP2D6*17 2.5
CYP2D6*29 1.60
CYP2D6*1xn 1.60
CYP2D6*34 1
CYP2D6*27 0.7
CYP2D6*10xn 0.3
CYP2D6*43 0.3
CYP2D6*46 0.3
Total 100%
doi:10.1371/journal.pone.0028943.t003
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[25] and a bit lower than the Croatians (14%) [20] but not as high
as what was reported in other Caucasians [12,24]. Three
individuals (2%) were homozygous for CYP2D6*4 and were
categorized as being PMs. Other defective alleles such as (*3,*5
and*6) could not be detected perhaps due to the small sample size
(n=151) we used for genotyping. Because of the fact that patients
with CYP2D6*4 are PMs they are more than likely to develop side
effects with normal doses of CYP2D*6-dependent antidepressants,
particularly because most of these drugs have narrow therapeutic
windows. Therefore drugs like tricyclic antidepressants (TCAs),
which have a narrow therapeutic window and venalaxine are
going to pose problems in these patients. Therefore lower doses to
approximately half the therapeutic doses of TCA are recom-
mended [26,27]. The opposite is true of UMs who need higher
doses of CYP2D6-dependent drugs to reach therapeutic levels.
Individuals were considered as IMs if they had one CYP2D6
allele with a decreased enzyme activity (*9,*10,*17,*29 or *41)
together with a non-functional allele (e.g. *3,*4,*4xn,*5,*6,*7,*8 or
*11) [23] or if they had two partially functional alleles. Among the
17 variant CYP2D6 alleles that were found in the UAE population,
CYP2D6*41 allele had a high frequency of 15.2% which is higher
than what was reported in other Caucasians (8.5%) [1], while
closer to what was reported in Palestinians (12.7%) [25].
CYP2D6*41 occurs in 22% of Ethiopians [28]. In Asia (1%) and
Africa (1–2%), it occurs in a lower frequency than in Caucasians
(10%) [26]. CYP2D6*41/*null form nearly 50–70% of all
Caucasian IMs [29]. In this study group 4.6% had CYP2D6*41/
*null (*41/*4) genotype while 8.6% had CYP2D6*IM/*IM
(e.g.*41/*41, *10/*10,*10/*41 and *17/*17). CYP2D6*10 and
*17 cause a decrease in the enzyme activity. The frequency of
CYP2D6*10 is relatively high in Asia (51%) and therefore nearly
25% of Asians are classified as IMs [12]. Black Africans and
African-Americans have high frequencies of CYP2D6*17 allele (up
to 35%) and that is the reason why the majority of them are IMs
[16]. On the other hand, null alleles are much rarer in Asia and
Africa than in Caucasians [1]. CYP2D6*10 and CYP2D6*17 were
found in UAE at a low frequencies of 3.3% and 2% respectively,
and this was expected as they occurred in even lower frequencies
in some other Caucasians.
UMs are characterized by faster rate of drug metabolism caused
by the presence of multiple active functional CYP2D6 genes (at
least 3 copies) on one individual allele. Consequently these subjects
do not reach the therapeutic plasma levels even at normal drug
doses. Alleles with multiple gene copies were found in high
frequencies only in some regions such as Saudi Arabia (21%) [21]
and Ethiopia (29%) [28], while in the rest of the world the
frequencies do not exceed 10% [26,30]. In UAE, the most
common duplicated alleles are *1 and *2 where CYP2D6*2xn
occurred in 4.3% which is close to Palestinian’s frequency (4.9%)
Table 4. The number of active alleles in the sample studied
(n=151).
Number of active alleles N %
0 active alleles 3 2
1 active allele 27 17.9
2 active alleles 104 68.9
.2 active alleles 17 11.3
doi:10.1371/journal.pone.0028943.t004
Table 5. The observed distribution of CYP2D6 known
genotypes and their predicted phenotypes in the recruited
individuals (n=151).
#
CYP2D6
genotype
Predicted
phenotype N %
No of active
alleles
1 *1/*1(wild type) Homozygous EM 31 20.5 2
2 *1/*1xn Homozygous UM 1 0.7 3
3 *1/*2 Heterozygous EM 17 11.3 2
4 *1/*2xn Heterozygous UM 5 3.3 3
5 *2/*2 Homozygous EM 3 2 2
6 *2xn/*2 Homozygous UM 1 0.7 3
7 *2/*4 Heterozygous EM 3 2 1
8 *2xn/*4 Heterozygous EM 2 1.3 2
9 *2/*41 Heterozygous EM 2 1.3 2
10 *2xn/*41 Heterozygous UM 1 0.7 3
11 *2/*39 Heterozygous EM 4 2.6 2
12 *2xn/*39 Heterozygous UM 2 1.3 3
13 *2xn/*10 Heterozygous UM 1 0.7 3
14 *2xn/*17 Heterozygous UM 1 0.7 3
15 *2/*29 Heterozygous EM 1 0.7 2
16 *1/*41 Heterozygous EM 14 9.3 2
17 *1xn/*41 Heterozygous UM 1 0.7 3
18 *1/*4 Heterozygous EM 8 5.3 1
19 *1/*35 Heterozygous EM 1 0.7 2
20 *1/10 Heterozygous EM 2 1.3 2
21 *1xn/10 Heterozygous UM 1 0.7 3
22 *1/*34 Heterozygous EM 3 2 2
23 *1/*17 Heterozygous EM 1 0.7 2
24 *1/*27 Heterozygous EM 1 0.7 2
25 *1xn/*27 Heterozygous UM 1 0.7 3
26 *1/*29 Heterozygous EM 1 0.7 2
27 *1xn/*39 Heterozygous UM 1 0.7 4
28 *1/*46 Heterozygous EM 1 0.7 2
29 *4/*4 Homozygous PM 3 2 0
30 *4/*41 Heterozygous IM 6 4 1
31 *4/*29 Heterozygous IM 1 0.7 1
32 *4/*43 Heterozygous EM 1 0.7 1
33 *41/*41 Homozygous IM 8 5.3 2
34 *35/*35 Homozygous EM 1 0.7 2
35 *10/*10 Homozygous IM 1 0.7 2
36 *29/*29 Homozygous IM 1 0.7 2
37 *17/*17 Homozygous IM 1 0.7 2
38 *17/*41 Heterozygous IM 1 0.7 2
39 *17/*39 Heterozygous EM 1 0.7 2
40 *10/*41 Heterozygous IM 1 0.7 2
41 *10xn/*41 Heterozygous UM 1 0.7 3
42 *10/*35 Heterozygous EM 1 0.7 2
43 *35/*39 Heterozygous EM 2 1.3 2
44 *39/*41 Heterozygous EM 2 1.3 2
EM extensive metabolizer, PM poor metabolizer, UM ultrarapid metabolizer and
IM intermediate metabolizer.
doi:10.1371/journal.pone.0028943.t005
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and Africans (0–2%) but still lower than Saudi Arabians and
African Ethiopians (10–16%) [7]. CYP2D6*1xn occurred only in
1.6% of the Emiratis while it reached 3.7% in some Middle
Eastern regions [25].
Kouhi et al. [30] determined the frequency of four CYP2D6
alleles in Iran. He found that CYP2D6*2 that encode for an EM
phenotype occurred in a frequency of 32% which when compared
to what we found in UAE (12.2%) is considered high. CYP2D6*4
occurred in 12.5% of Iranians and this is somehow close to the
frequency in UAE (9%). CYP2D6*10 occurred more frequently in
Iran (9%) than in UAE (3.3%) while CYP2D6*17 was completely
absent in Iran with a 2% frequency in UAE nationals. In addition,
Iran has more PMs (4%) than UAE (2%), while they were 8% in
Palestinians, 17% in Jews of Russian origin, and 0% in Jews of
Yemeni and Ethiopian extraction [31].
In conclusion, CYP2D6 gene can be considered a challenge
for genotyping because its polymorphisms are numerous
including not only SNPs but also gene duplication and deletion.
However, our approach of direct DNA sequencing of all the
coding regions and most of the intronic noncoding regions
provided us with the opportunity to capture most of the
variants. Our study showed that CYP2D6 is polymorphic in the
UAE population with a different distribution compared with
other populations but there were some similarities especially
with Palestinians. New SNPs, New alleles and atypical
genotypes were observed in the UAE study group (Table 1
and 2). Expanding the number of participants and further
studies are anticipated to enrich the CYP2D6 nomenclature
database and increase our knowledge of CYP2D6 among
Emiratis. In addition, we believe that family based studies
would be helpful in determining the full haplotypes in this
population. MRs especially for the new alleles should be
measured to verify the corresponding phenotype.
Materials and Methods
Subjects blood sampling
Ethics Statement. This study was approved by Al-Ain
District Human Research Ethics and the Faculty of Medicine
and Health Sciences, UAE University Committee (07/148) and
informed consent was obtained from all subjects.
Blood samples were collected from 151 Emiratis: 101 of
them were unrelated UAE nationals who suffered from
endogenous depression and were being treated with antide-
pressants at Al Ain Hospital inpatient and outpatient
psychiatry clinics as well as Tawam Hospital outpatient clinic.
The other 50 individuals were blood donors randomly selected
from healthy population.
Extraction of DNA
DNA was extracted from peripheral leukocytes using a whole-
blood Qiagen extraction kit (Flexigene DNA isolation kit). The
isolated genomic DNA samples were kept in sterile plastic vials at
4uC until analysis or stored at 220u.
PCR amplification of the CYP2D gene and DNA
sequencing
Primer design and PCR amplification was achieved under
standard conditions describedb yM a s i m i r e m b w ae ta l .( 1 9 9 6 )
[8]. The oligonucleotides used for PCR are listed in table S1.
DNA was sequenced using the BigDye Terminator kit v3.1with
a 3130x/genetic analyzer system (Applied Biosystems) following
ExoSAP-ITH (USB Corporation) treatment of the PCR
products. Cycle sequencing was performed under standard
conditions recommended by the manufacturers (Applied Bio-
systems Inc.). Oligonucleotides used for sequencing are listed in
table S2.
Analysis of sequencing data
For each patient the produced sequences were aligned with the
original CYP2D6 sequence (NM_000106.4) using ClustalW2
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) to detect the pres-
ence of SNPs or mutations as well as to define each patient’s
genotype. Expasy Translate tool (http://us.expasy.org/tools/dna.
html) was used to translate DNA sequences into their protein
sequences to examine the influence of the DNA changes at the
protein level and thus the enzymatic activity.
TaqMan RT-PCR
CYP2D6 gene copy number was determined using TaqManH
real-time quantitative PCR (ABI 7900 Fast Real-Time PCR
system; Applied Biosystems). Real time data were collected by the
SDS 2.1 software, and data were analyzed using the relative
quantification (DDCT) method. Three calibrators (containing one,
two or three CYP2D6 gene copies DNA samples from Coriell Inc.,
http://ccr.coriell.org) were included in each run for the accuracy
of the results and each sample was normalized to RNaseP to
produce DCT. All samples were then normalized to the calibrator
(NA17120) sample to determine DDCT. Relative quantity (RQ)
values were then calculated and multiplied by 2 to produce
CYP2D6 gene copy number.
Statistical analysis
The statistical analysis was conducted by SPSS 17.0 (for
windows) to calculate frequencies. The level of significant of P
value was set at less than 0.05.
Supporting Information
Table S1 Primers for PCR amplification of CYP2D6
gene (exons 1–9).
(DOCX)
Table S2 Primers for CYP2D6 sequencing.
(DOCX)
Figure 1. CYP2D6 protein showing position 366 where there is
a substitution from phenylalanine to serine amino acid.
Molecular modeling was performed using RasMol (http://www.openrasmol.
org). A) 366 Phenylalanine is large hydrophobic amino acid B) 366 Serineis a
polar uncharged small Amino acid.
doi:10.1371/journal.pone.0028943.g001
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